Identification
- Summary
Monopotassium phosphate is an ionic compound used for electrolyte replenishment and total parenteral nutrition (TPN) therapy.
- Brand Names
- Dextrose and Electrolyte No. 75, Ionosol-MB, Isolyte S, Isolyte S pH 7.4, Isoplate, K-phos, K-phos Neutral, K-phos No 2, Tis-U-sol
- Generic Name
- Monopotassium phosphate
- DrugBank Accession Number
- DB09413
- Background
Monopotassium phosphate, MKP, (also potassium dihydrogenphosphate, KDP, or monobasic potassium phosphate), KH2PO4, is a soluble salt of potassium and the dihydrogen phosphate ion. It is a source of phosphorus and potassium as well as a buffering agent. It can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low.
- Type
- Small Molecule
- Groups
- Approved, Investigational, Vet approved
- Structure
Structure for Monopotassium phosphate (DB09413)
- Weight
- Average: 136.0855
Monoisotopic: 135.932776925 - Chemical Formula
- H2KO4P
- Synonyms
- Monobasic potassium phosphate
- Monopotassium dihydrogen monophosphate
- Monopotassium dihydrogen orthophosphate
- Monopotassium dihydrogen phosphate
- Monopotassium monophosphate
- Monopotassium orthophosphate
- Phosphoric acid, monopotassium salt
- Potassium acid phosphate
- Potassium biphosphate
- Potassium dihydrogen orthophosphate
- Potassium dihydrogen phosphate
- Potassium phosphate
- Potassium phosphate monobasic
- Potassium phosphate monobasic (anhydrous)
- Potassium phosphate, monobasic
- Potassium phosphate,monobasic
- External IDs
- E-340(I)
- INS NO.340(I)
- INS-340(I)
Pharmacology
- Indication
Used in buffers (determination of pH, pharmaceutical production, urinary acidifier, paper processing, baking powder, and food), nutrient solutions, yeast foods, special liquid fertilizers, sonar systems and other electronic applications; Used as a nutritional supplement in foods, a nonlinear optical material for laser use, and in wastewater treatment;
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Potassium is the major cation of intracellular fluid and is essential for maintenance of acid-base balance, isotonicity, and electrodynamic characteristics of the cell. Potassium is an important activator in many enzymatic reactions and is essential to a number of physiologic processes including transmission of nerve impulses; contraction of cardiac, smooth, and skeletal muscles; gastric secretion; renal function; tissue synthesis; and carbohydrate metabolism. Phosphate is a major intracellular anion that participates in providing energy for metabolism of substrates and contributes to important metabolic and enzymatic reactions in almost all organs and tissues. Phosphate exerts a modifying influence on calcium concentrations, a buffering effect on acid-base equilibrium, and has a major role in the renal excretion of hydrogen ions.
- Mechanism of action
hosphorus has a number of important functions in the biochemistry of the body. The bulk of the body's phosphorus is located in the bones, where it plays a key role in osteoblastic and osteoclastic activities. Enzymatically catalyzed phosphate-transfer reactions are numerous and vital in the metabolism of carbohydrate, lipid and protein, and a proper concentration of the anion is of primary importance in assuring an orderly biochemical sequence. ln addition, phosphorus plays an important role in modifying steady-state tissue concentrations of calcium. Phosphate ions are important buffers of the intracellular fluid, and also play a primary role in the renal excretion of the hydrogen ion. Oral administration of inorganic phosphates increases serum phosphate levels. Phosphates lower urinary calcium levels in idiopathic hypercalciuria.
- Absorption
Potassium salts are well absorbed from the GI tract. Ingested phosphates are absorbed from the gastrointestinal tract. However, the presence of large amounts of calcium or aluminum may lead to formation of insoluble phosphate and reduce the net absorption. Vitamin D stimulates phosphate absorption.
- Volume of distribution
Potassium first enters the extracellular fluid and is then actively transported into the cells where its concentration is up to 40 times that outside the cell. Dextrose, insulin, and oxygen facilitate movement of potassium into cells.
- Protein binding
In healthy adults, plasma potassium concentrations generally range from 3.5-5 mEq/L. Plasma concentrations up to 7.7 mEq/L may be normal in neonates.
- Metabolism
- Not Available
- Route of elimination
Renal (90%) and fecal (10%) Phosphates Potassium is excreted mainly by the kidneys. Small amounts of potassium may be excreted via the skin and intestinal tract, but most of the potassium excreted into the intestine is later reabsorbed.
- Half-life
In healthy children with phosphate overdose, half-life was 4.8 to 10.6 hours, and was prolonged to 17 hours in a child with renal insufficiency.
- Clearance
Phosphates are rapidly cleared by dialysis. Dialysis can also be used to treat other electrolyte abnormalities such as hypernatremia, hypocalcemia, and hypomagnesemia.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Rabbit : LD50 >4640mg/kg (skin) Rat : LdLo : 4640mg/kg (Oral)
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol Monopotassium phosphate may increase the hyperkalemic activities of Acebutolol. Aceclofenac Monopotassium phosphate may increase the hyperkalemic activities of Aceclofenac. Acemetacin Monopotassium phosphate may increase the hyperkalemic activities of Acemetacin. Acetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Monopotassium phosphate. Acetylsalicylic acid The serum concentration of Acetylsalicylic acid can be increased when it is combined with Monopotassium phosphate. - Food Interactions
- Take separate from antacids. Magnesium, calcium, or aluminum antacids may reduce the absorption of phosphate in K-phos.
- Take with a full glass of water. Dissolve K-Phos tablets in water then ingest.
- Take with food. Take K-Phos tablets at bedtime and with meals.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Potassium cation ionic 295O53K152 24203-36-9 NPYPAHLBTDXSSS-UHFFFAOYSA-N Phosphate ion ionic NK08V8K8HR 14265-44-2 NBIIXXVUZAFLBC-UHFFFAOYSA-K - Product Images
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image K Phos Original Tablet, soluble 500 mg/1 Oral Beach Products, Inc. 1977-03-29 Not applicable US 
K Phos Original Tablet, soluble 500 mg/1 Oral Carilion Materials Management 1977-03-29 Not applicable US 
Potassium Phosphate Monobasic Injection Solution 176 mg / mL Intravenous Sandoz Canada Incorporated 1987-12-31 Not applicable Canada 
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image DBL POTASSIUM DIHYDROGEN PHOSPHATE CONCENTRATED INJECTION Injection 1.361 g Intravenous PFIZER PRIVATE LIMITED 1991-05-21 Not applicable Singapore 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Artisial Monopotassium phosphate (32.6 mg / 100 mL) + Calcium chloride (16.625 mg / 100 mL) + Dipotassium phosphate (80.3 mg / 100 mL) + Magnesium chloride (5.875 mg / 100 mL) + Potassium chloride (62.45 mg / 100 mL) + Sodium chloride (86.55 mg / 100 mL) Liquid Buccal Jouveinal Inc. 1986-12-31 1996-09-09 Canada BİOFLEKS İZOLEKS-S pH 7.4 ÇÖZELTİSİ 1000 ML (PVC TORBA) SETLİ Monopotassium phosphate (0.00082 g/100ml) + Dipotassium phosphate (0.012 g/100ml) + Sodium gluconate (0.5 g/100ml) + Magnesium chloride hexahydrate (0.03 g/100ml) + Potassium chloride (0.037 g/100ml) + Sodium acetate trihydrate (0.37 g/100ml) + Sodium chloride (0.53 g/100ml) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2003-01-01 Not applicable Turkey 
BİOFLEKS İZOLEKS-S pH 7.4 ÇÖZELTİSİ 500 ML (PVC TORBA) SETLİ Monopotassium phosphate (0.00082 g/100ml) + Dipotassium phosphate (0.012 g/100ml) + Sodium gluconate (0.5 g/100ml) + Magnesium chloride hexahydrate (0.03 g/100ml) + Potassium chloride (0.037 g/100ml) + Sodium acetate trihydrate (0.37 g/100ml) + Sodium chloride (0.53 g/100ml) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2003-01-01 Not applicable Turkey BİOFLEKS İZOLEKS-S pH 7.4 ÇÖZELTİSİ 500 ML (PVC TORBA) SETSİZ Monopotassium phosphate (0.00082 g/100ml) + Dipotassium phosphate (0.012 g/100ml) + Sodium gluconate (0.5 g/100ml) + Magnesium chloride hexahydrate (0.03 g/100ml) + Potassium chloride (0.037 g/100ml) + Sodium acetate trihydrate (0.37 g/100ml) + Sodium chloride (0.53 g/100ml) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2003-01-01 Not applicable Turkey Clinimix 3 % G-E - Infusionsbeutel Monopotassium phosphate (2.6 g/l) + Amino acids (3 %) + Calcium chloride (0.33 g/l) + Dextrose, unspecified form (75 g/l) + Magnesium chloride (0.5 g/l) + Sodium acetate (2 g/l) + Sodium chloride (1 g/l) Injection, solution Parenteral Baxter Healthcare Gmb H 1996-05-15 Not applicable Austria 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral American Health Packaging 2014-05-13 2020-06-30 US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral Avera McKennan Hospital 2015-03-11 2017-05-24 US 
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral Cardinal Health 2012-06-28 2018-03-31 US 
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral Rising Pharmaceuticals, Inc. 2012-06-28 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral KAISER FOUNDATION HOSPITALS 2014-07-07 2018-01-31 US
Categories
- Drug Categories
- Acids
- Acids, Noncarboxylic
- Anions
- Buffers
- Cariostatic Agents
- Compounds used in a research, industrial, or household setting
- Dental Materials
- Electrolytes
- Ions
- Laboratory Chemicals
- Laxatives
- Phosphate salts
- Phosphoric Acids
- Phosphorus Acids
- Phosphorus Compounds
- Potassium Salt
- Protective Agents
- Replacement Preparations
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal oxoanionic compounds
- Sub Class
- Alkali metal phosphates
- Direct Parent
- Alkali metal phosphates
- Alternative Parents
- Inorganic salts / Inorganic oxides
- Substituents
- Alkali metal phosphate / Inorganic oxide / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- potassium salt, inorganic phosphate (CHEBI:63036)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4J9FJ0HL51
- CAS number
- 7778-77-0
- InChI Key
- GNSKLFRGEWLPPA-UHFFFAOYSA-M
- InChI
- InChI=1S/K.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1
- IUPAC Name
- potassium dihydrogen phosphate
- SMILES
- [K+].OP(O)([O-])=O
References
- General References
- External Links
- PubChem Compound
- 516951
- PubChem Substance
- 347827846
- ChemSpider
- 22914
- BindingDB
- 50004328
- 34322
- ChEBI
- 63036
- ChEMBL
- CHEMBL1200925
- Wikipedia
- Monopotassium_phosphate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Supportive Care Postoperative Complications / Regeneration Liver 1 3 Completed Treatment Hypercalcinuria / Kidney Stones 1 2 Not Yet Recruiting Treatment Nasopharyngeal Neoplasms 1 2 Unknown Status Treatment Hypophosphatemia / Osteopenia Of Prematurity 1 0 Completed Basic Science Hypoglycemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Liquid Buccal Injection, solution Parenteral Injection Intravenous 1.361 g Injection, solution Intravenous 1.361 g Liquid Intravenous Injection, solution Intravenous Tablet Oral Solution Intravenous Tablet, coated Oral Tablet, soluble Oral 500 mg/1 Solution Intravenous 0.775 g Liquid Topical Solution Parenteral Injection, solution Injection, solution Parenteral Injection, solution Parenteral 2 MEQ/ML Solution Parenteral Injection, solution, concentrate Intravenous Tablet Parenteral Solution Intravenous 176 mg / mL Injection Intravenous Injection, solution, concentrate Intravenous Solution, concentrate Intravenous Powder Oral Solution Irrigant Irrigation Solution Irrigation Liquid Irrigation - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US10632150 No 2020-04-28 2039-04-19 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1 Chemaxon pKa (Strongest Acidic) 1.8 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 80.59 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 13.53 m3·mol-1 Chemaxon Polarizability 5.53 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-000i-2900000000-705bf4c492a6a3f08fca - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 105.4458532 predictedDarkChem Lite v0.1.0 [M-H]- 123.80129 predictedDeepCCS 1.0 (2019) [M+H]+ 127.12847 predictedDeepCCS 1.0 (2019) [M+Na]+ 135.90962 predictedDeepCCS 1.0 (2019)
Drug created at November 30, 2015 19:10 / Updated at September 06, 2023 02:10